0001493152-24-018465.txt : 20240509 0001493152-24-018465.hdr.sgml : 20240509 20240509162942 ACCESSION NUMBER: 0001493152-24-018465 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 24931189 BUSINESS ADDRESS: STREET 1: WATERVIEW PLAZA, SUITE 310 STREET 2: 2001 ROUTE 46 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: WATERVIEW PLAZA, SUITE 310 STREET 2: 2001 ROUTE 46 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 8-K 1 form8-k.htm
false 0001054102 0001054102 2024-05-09 2024-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 9, 2024

 

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

delaware   0-24249   22-2919486

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Waterview Plaza, Suite 310

2001 Route 46,

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 9, 2024, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended March 31, 2024. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
99.1   Press Release, dated May 9, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Biosciences, Inc.
     
  By: /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date: May 9, 2024

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results

 

  ● Q1 Revenue of $10.3 million; a 4% increase year-over-year
  ● Q1 Test volume up 10% year over year to record levels

 

PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update.

 

First quarter Net Revenue was $10.3 million. Operating expenses for the first quarter were approximately 2% lower than the same period of 2023. Income from continuing operations in the first quarter of 2024 was $0.6 million. an improvement from the prior year quarter of $0.4 million. “The Company achieved record test volume and cash collections, while reducing operating expenses, in the first quarter of 2024. Test volume, test revenue, and cash collections increased over the prior year quarter, driven by increased volume and collection initiatives,” said Chris McCarthy, Chief Financial Officer. “The cash position of the Company allowed for additional investments in our salesforce, while simultaneously improving income from continuing operations. This also supported additional principal payments on our long-term debt agreement, continuing to improve the Company’s balance sheet.” McCarthy added.

 

“Q1 2024 represented record testing volume for the Company, resulting in the achievement of continued profitability and positive cash flow,” stated Tom Burnell, President and CEO. “Continued adoption of the Company’s proprietary molecular diagnostics tests (ThyGeNEXT® + ThyraMIR®v2 and PancraGEN®) by physicians and medical professionals has fueled the continued growth trajectory of the Company.” Burnell added, Q1 2024 marked the fifteenth consecutive quarter of year-over-year volume growth for the Company”.

 

First Quarter and 2024 Financial Performance

 

For the First Quarter of 2024 as Compared to the First Quarter of 2023

 

  ● Net Revenue was $10.3 million, an increase of 4% from $9.8 million for the prior year quarter
     
  ● Gross Profit percentage was 59% compared to 61% for the prior year quarter
     
  ● Operating income was $0.9 million vs operating income of $0.7 million in the prior year quarter
     
  ● Income from continuing operations was $0.6 million vs income from continuing operations of $0.4 million in the prior year quarter
     
  ● Adjusted EBITDA was $1.0 million vs $1.2 million in the prior year quarter
     
  ● Q1 2024 cash collections totaled $10.2 million
     
  ● March 31, 2024 cash balance was $2.8 million vs March 31, 2023 cash balance of $5.6 million, driven by $3.1 million additional long-term debt paydown

 

 
 

 

About Interpace Biosciences

 

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

 

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA®, a “molecular only” version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.

 

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

 

Forward-looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the reimbursement of the Company’s tests being subject to review by CMS, the Company’s ability to continue to perform, bill and receive reimbursement for our PancraGEN® molecular test under the existing local coverage determination (“LCD”), given that such LCD is currently under review by Novitas Solutions, Inc., the Company’s Medicare administrative contractor, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings with Comerica Bank and BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the possible removal of the Company’s common stock from trading on the OTCQX®.

 

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

Contacts:

 

Investor Relations

Interpace Biosciences, Inc.

(855)-776-6419

Info@Interpace.com

 

 
 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except per share data)

 

   Three Months Ended 
   March 31, 
   2024   2023 
         
Revenue, net  $10,273   $9,826 
Cost of revenue   4,202    3,848 
Gross Profit   6,071    5,978 
           
Sales and marketing   2,821    2,342 
Research and development   137    149 
General and administrative   2,239    2,494 
Acquisition amortization expense   -    318 
Total operating expenses   5,197    5,303 
           
Operating income   874    675 
Interest accretion expense   (19)   (35)
Note payable interest   (197)   (225)
Other (expense) income, net   (82)   19 
Income from continuing operations before tax   576    434 
Provision for income taxes   4    4 
Income from continuing operations   572    430 
           
Loss from discontinued operations, net of tax   (104)   (79)
           
Net income  $468   $351 
           
Basic income (loss) per share of common stock:          
From continuing operations  $0.13   $0.10 
From discontinued operations   (0.02)   (0.02)
Net loss per basic share of common stock  $0.11   $0.08 
           
Diluted income (loss) per share of common stock:          
From continuing operations  $0.13   $0.10 
From discontinued operations   (0.02)   (0.02)
Net loss per diluted share of common stock  $0.11   $0.08 
           
Weighted average number of common shares and common share equivalents outstanding:          
Basic   4,370    4,307 
Diluted   4,384    4,308 

 

 
 

 

Selected Balance Sheet Data (Unaudited)

($ in thousands)

 

   March 31,   December 31, 
   2024   2023 
Cash and cash equivalents  $2,812   $3,498 
           
Total current assets   9,416    10,322 
Total current liabilities   18,973    17,474 
           
Total assets   12,142    13,021 
Total liabilities   26,747    28,157 
Total stockholders’ deficit   (61,141)   (61,672)

 

Selected Cash Flow Data (Unaudited)

($ in thousands)

 

   For the Three Months Ended 
   March 31, 
   2024   2023 
Net income  $468   $351 
           
Net cash (used in) provided by operating activities  $(58)  $1,133 
Net cash used in investing activities   (28)   (65)
Net cash used in financing activities   (600)   (300)
Change in cash and cash equivalents   (686)   768 
Cash and cash equivalents – beginning   3,498    4,828 
Cash and cash equivalents – ending  $2,812   $5,596 

 

 
 

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

   Three Months Ended 
   March 31, 
   2024   2023 
Income from continuing operations (GAAP Basis)  $572   $430 
Depreciation and amortization   52    356 
Stock-based compensation   79    192 
Taxes expense   4    4 
Interest accretion expense   19    35 
Note payable interest   197    225 
Interest income   (16)   - 
Change in fair value of note payable   98    (33)
Adjusted EBITDA  $1,005   $1,209 

 

Non-GAAP Financial Measures

 

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

 

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation and ESPP plans, interest and taxes, and other non-cash expenses including change in fair values of notes payable and contingent consideration. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

 

 EX-101.SCH 3 idxg-20240509.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 idxg-20240509_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 idxg-20240509_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity File Number 0-24249
Entity Registrant Name INTERPACE BIOSCIENCES, INC.
Entity Central Index Key 0001054102
Entity Tax Identification Number 22-2919486
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Waterview Plaza
Entity Address, Address Line Two Suite 310
Entity Address, Address Line Three 2001 Route 46
Entity Address, City or Town Parsippany
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07054
City Area Code (855)
Local Phone Number 776-6419
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interpace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm idxg-20240509.xsd idxg-20240509_lab.xml idxg-20240509_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "IDXG", "nsuri": "http://interpace.com/20240509", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "idxg-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "idxg-20240509_lab.xml" ] }, "presentationLink": { "local": [ "idxg-20240509_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 60, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://interpace.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-018465-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-018465-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001054102 2024-05-09 2024-05-09 iso4217:USD shares iso4217:USD shares false 0001054102 8-K 2024-05-09 INTERPACE BIOSCIENCES, INC. DE 0-24249 22-2919486 Waterview Plaza Suite 310 2001 Route 46 Parsippany NJ 07054 (855) 776-6419 Not Applicable false false false false false